CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on March 8, 2018 at
8:00 a.m. ET to discuss fourth quarter 2017 results and provide a
general business update.
To access the conference call, please dial 844-277-9450 (domestic) or
336-525-7139 (international) and reference the conference ID number
5092388. To join the live webcast, please visit the “Investors and
Media” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning
approximately two hours after the event and will be archived for
approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the natural state of bacterial diversity and function is
imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough
Therapy and Orphan Drug designations from the U.S. Food and Drug
Administration and is in Phase 3 development for multiply recurrent C. difficile infection.
Seres’ clinical candidate SER-287 has successfully completed a Phase 1b
study in patients with mild-to-moderate Ulcerative Colitis. Seres is
also developing SER-262, the first ever synthetic microbiome therapeutic
candidate, in a Phase 1b study in patients with primary C.
difficile infection. For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180302005073/en/
Source: Seres Therapeutics, Inc.
IR or PR Contact:
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor
Relations and Corporate Communications